Viatris Inc. (VTRS)
Company Description
Viatris Inc. operates as a healthcare company worldwide.
The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Country | United States |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 38,000 |
CEO | Scott Andrew Smith |
Contact Details
Address: 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 United States | |
Phone | (724) 514-1465 |
Website | viatris.com |
Stock Details
Ticker Symbol | VTRS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001792044 |
CUSIP Number | 92556V106 |
ISIN Number | US92556V1061 |
Employer ID | 83-4364296 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Scott Andrew Smith | Chief Executive Officer and Director |
Rajiv Malik | President and Executive Director |
Anthony Mauro | President of Developed Markets |
Theodora Mistras | Chief Financial Officer |
Sanjeev Kumar Sethi | Chief Operating Officer |
Paul B. Campbell | Chief Accounting Officer, Senior Vice President and Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 144 | Filing |
Mar 5, 2024 | 144 | Filing |
Mar 5, 2024 | 144 | Filing |
Mar 4, 2024 | 144 | Filing |
Feb 28, 2024 | 10-K | Annual Report |
Feb 28, 2024 | 8-K | Current Report |
Feb 23, 2024 | 144 | Filing |
Feb 15, 2024 | 144 | Filing |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |